Arkolith/Insider Trading/FNCH/Form 4/A

Blischak Matthew P.

Chief Executive OfficerFinch Therapeutics Group, Inc. (FNCH) · full profile →Form 4/A · filed Jun 23, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 9, 2023Grant(A)963K—$0963K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0000899243-23-016365) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML